Navigation Links
Unigene Recieves 2013 Drug Delivery Partnerships Industry Achievement Award
Date:2/13/2013

"   

As the leader in the design, delivery, manufacture and development of peptide-based therapeutics, Unigene is focused on advancing its own pipeline of novel, proprietary peptide product candidates focused on metabolic disease and inflammation as well as exploiting its industry-leading Peptelligence™ platform of peptide oral drug delivery and manufacturing assets, expertise and capabilities by building a robust portfolio of strategically partnered opportunities.

"We are very proud to recognize Unigene as the DDP Innovation Award for the second year in a row," remarked Heather King , Drug Deliver Partnerships. "Without question, Unigene has secured its position as a true innovator in oral peptide delivery and, more broadly, throughout the drug development and delivery industry."

About Unigene Laboratories, Inc.

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform.  Peptelligence™ encompasses extensive intellectual property covering drug delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence.  Core Peptelligence™ assets include proprietary oral and nasal peptide drug delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements, including statements relating to Unigene's ability to build a robust portfolio of proprietary partnerships in peptide-based therapeutics based on its Peptelligence™ platform. These forward-looking statements are not guarantees of
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Unigenes Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
2. Unigene and Tarix Pharmaceuticals Enter Definitive Licensing Agreement for "Peptelligence-Engineered" TXA127
3. Unigene to Announce Third Quarter 2012 Financial Results on November 20, 2012
4. Unigene To Present at the 2012 Obesity Societys 30th Annual Scientific Meeting
5. Unigene and Tarix Pharmaceuticals Report Highly Increased Oral Bioavailability of "Peptelligence-engineered" TXA127
6. Unigene Provides Update Following Recent EMA Recommendation on Calcitonin-Containing Medicines
7. Unigenes Oral PTH Phase 2 Proof-of-Concept Data to be Presented at Upcoming Scientific Conferences
8. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
9. Unigene to Present at TIDES 2012
10. Unilife to Showcase Broad Portfolio of Innovative, Differentiated Injectable Drug Delivery Systems at Pharmapack Europe
11. BioDelivery Sciences to Present at the 15th Annual BIO CEO and Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Equity Research highlights Epizyme (Nasdaq: EPZM - Free Report ... PNRA - Free Report ) as the Bear of the Day. ... FOLD - Free Report ), Sanofi (NYSE: SNY - ... ). Here is a synopsis of all five stocks: ... The biotech bull market is far from over due to ...
(Date:8/22/2014)...  - MediaLINC unlocks the real ... general availability of MediaLINC - its innovative ... education, entertainment and clinical content direct to standard HD ... " Lincor has already been phenomenally ... bedside smart devices, " comments Dan Byrne , ...
(Date:8/22/2014)... Calif. , Aug. 22, 2014  WaferGen Bio-systems, ... underwritten public offering of units of common stock and ... gross proceeds of $20 million, prior to deducting underwriting ... Company.  The shares and warrants are immediately separable and ... are expected to begin trading on The NASDAQ Stock ...
Breaking Medicine Technology:Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Lincor Unveils Next Generation TV-based Patient Engagement Solution 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4
... ("CTI") (NASDAQ and MTA: CTIC) announced today the results from ... 2011. At the meeting, shareholders approved the proposal to amend ... total number of authorized shares and authorized shares of common ... Headquartered in Seattle, CTI is a biopharmaceutical ...
... June 17, 2011 The St. Francis Heart Center ... first post-FDA approval surgery in the United States using a new ... Contour 3D™ Annuloplasty Ring, the device, which is manufactured by ... the natural valve,s shape and size. The procedure ...
Cached Medicine Technology:Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders 2Franciscan St. Francis Heart Center Surgeon Pioneers Use of Heart Valve Repair Ring 2Franciscan St. Francis Heart Center Surgeon Pioneers Use of Heart Valve Repair Ring 3
(Date:8/22/2014)... 2014 As the controversy surrounding ... in uterine surgeries continues to grow, Bernstein Liebhard ... decided to limit coverage of uterine morcellation. According ... Cross-Blue Shield of Massachusetts will no longer cover ... as of September 1, 2014. Other insurers in ...
(Date:8/22/2014)... Natural Clear Vision , a how-to guide and ... from legally blind to perfect 20/20 vision has caught the ... “There is a huge portion of the population today that ... people just think that’s the way it will always be ... pretty risky at times,” reports Michaels. “This program is a ...
(Date:8/22/2014)... August 22, 2014 Mi40x , the ... research to show people how they can use a simple ... only a matter of weeks has caught the attention of ... is one of the most well-known bodybuilders in the industry, ... he has today, that in itself is a testament to ...
(Date:8/22/2014)... DENVER For the first time an oncogenic somatic ... during transfection) protein has been identified in small cell ... mutation within SCLC cell lines produced increased intracellular signaling ... form of lung cancer representing 15% of all lung ... representing 85% of lung cancer, has been extensively examined ...
(Date:8/22/2014)... complex autoimmune disease that affects 1 to 2 ... cope with pain, disability and joint disfigurements, but ... life and marital functioning. While many pharmacological advances ... is common. In addition, some patients avoid newer ... effects. Because of this, there is interest in ...
Breaking Medicine News(10 mins):Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:Study shows cognitive-behavioral coping skills training has positive effects on rheumatoid arthritis 2
... in two years, California researcher says , , FRIDAY, Feb. 1 ... the progress of the disease in 90 percent of the ... turned the cancer into a chronic, manageable disease," said W. ... Feb. 1 issue of Cancer Research . , Twenty ...
... The globally active precious,metal and technology group Heraeus ... Interventional Business of Synovis Life,Technologies, Inc., based in ... 31, 2008. With this acquisition, the Heraeus Medical,Components ... facilities in the,U.S., Germany, Switzerland and Puerto Rico., ...
... 1 Lifespring Health,sponsors the Kaiser Permanente San Francisco ... charity event benefiting the Hemophilia Foundation of,Northern California, Support ... House., Set to take place on Feb. 3, ... course is ranked as one of the most scenic,in ...
... Piwek to Assist in Generating New Retail Licensing ... Inc. (OTC,Bulletin Board: SKVI) ( http://www.skinvisible.com ), a ... patented dermatology,products with their proprietary polymer delivery system ... selected as a new member of,the Company,s Board ...
... and vigilance show a relationship with core body temperature ... high during the daytime, skin temperature is low, which ... temperature is low at night time, skin temperature is ... suffering from narcolepsy, however, direct manipulations of their skin ...
... , UCLA and University of North Carolina researchers have found ... sexual and/or physical abuse may have a heightened brain response ... IBS is a condition that affects 10 to 15 percent ... constipation or both. , Researchers used brain ...
Cached Medicine News:Health News:Experimental Vaccine Halts Prostate Cancer in Mice 2Health News:Experimental Vaccine Halts Prostate Cancer in Mice 3Health News:Heraeus Strengthens Medical Components Business 2Health News:Skinvisible Appoints New Board Member 2Health News:Skinvisible Appoints New Board Member 3Health News:Changes in narcoleptics' skin, core body temperatures affect their vigilance and sleepiness 2Health News:Changes in narcoleptics' skin, core body temperatures affect their vigilance and sleepiness 3
... Introducing the new PRONEB® ULTRA compressor. This ... time while delivering more medication to the ... LC PLUS® or PARI LC STAR® Reusable ... optimized for inhalation and retention into the ...
... PRONEB® ULTRA compressor. This high output compressor ... more medication to the patient's lungs. When ... PARI LC STAR® Reusable Nebulizer, the particle ... and retention into the lungs. With less ...
... The new PARI TREK™ Compact Compressor ... take their aerosol treatments anywhere and everywhere. ... powerful. Three versatile power source optionsworldwide AC ... and rechargeable battery, permit patients the freedom ...
... Air., ,Allied Healthcares Timeter® PCS 414 portable ... air compressors that you may wonder if its ... 414 features a durable, mar-resistant steel case thats ... weighs only 26.5 pounds. The PCS 414 has ...
Medicine Products: